StockData
Quest Diagnostics Inc logo

Quest Diagnostics Inc (DGX) stock

DGXNYSEServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 23, 2026Score 12/3010% above fair value
$259.09−0.60 (-0.23%)

Close on Nov 19, 2026Market cap $28.50BP/E 25.8Yield –

Quest Diagnostics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Quest Diagnostics's free cash flow for the twelve months ending Sep 30, 2026 was $1.38B, down 1.3% year over year. For fiscal 2025 it was $1.36B, up 49.5% from the year before. Over ten years it grew 9.3% a year on average. The highest annual figure on record is $1.83B in fiscal 2021.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.36B+49.5%
FY2024Dec 31, 2024$909.00M+5.2%
FY2023Dec 31, 2023$864.00M-34.2%
FY2022Dec 31, 2022$1.31B-28.2%
FY2021Dec 31, 2021$1.83B+15.3%
FY2020Dec 31, 2020$1.59B+88.3%
FY2019Dec 31, 2019$843.00M+3.2%
FY2018Dec 31, 2018$817.00M-11.5%
FY2017Dec 31, 2017$923.00M+12.2%
FY2016Dec 31, 2016$823.00M+47.5%
FY2015Dec 31, 2015$558.00M-12.3%
FY2014Dec 31, 2014$636.00M+51.1%
FY2013Dec 31, 2013$421.00M-58.1%
FY2012Dec 31, 2012$1.01B+36.9%
FY2011Dec 31, 2011$734.00M-19.6%
FY2010Dec 31, 2010$912.65M+9.9%
FY2009Dec 31, 2009$830.49M-2.3%
FY2008Dec 31, 2008$850.37M+20.1%
FY2007Dec 31, 2007$707.82M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$445.00M+6.2%
Q2 FY2026Jun 30, 2026$459.00M+5.3%
Q1 FY2026Mar 31, 2026$164.00M-16.8%
Q4 FY2025Dec 31, 2025$307.00M-10.0%
Q3 FY2025Sep 30, 2025$419.00M+67.6%
Q2 FY2025Jun 30, 2025$436.00M+62.7%
Q1 FY2025Mar 31, 2025$197.00M+294.0%
Q4 FY2024Dec 31, 2024$341.00M-25.1%
Q3 FY2024Sep 30, 2024$250.00M+145.1%
Q2 FY2024Jun 30, 2024$268.00M-21.2%
Q1 FY2024Mar 31, 2024$50.00M–
Q4 FY2023Dec 31, 2023$455.00M+143.3%
Q3 FY2023Sep 30, 2023$102.00M-73.4%
Q2 FY2023Jun 30, 2023$340.00M+4.3%
Q1 FY2023Mar 31, 2023-$33.00M-107.9%
Q4 FY2022Dec 31, 2022$187.00M-44.5%
Q3 FY2022Sep 30, 2022$384.00M-18.6%
Q2 FY2022Jun 30, 2022$326.00M-13.3%
Q1 FY2022Mar 31, 2022$417.00M-35.3%
Q4 FY2021Dec 31, 2021$337.00M-11.1%
Q3 FY2021Sep 30, 2021$472.00M-38.8%
Q2 FY2021Jun 30, 2021$376.00M+37.7%
Q1 FY2021Mar 31, 2021$645.00M+293.3%
Q4 FY2020Dec 31, 2020$379.00M+115.3%
Q3 FY2020Sep 30, 2020$771.00M+279.8%
Q2 FY2020Jun 30, 2020$273.00M+15.7%
Q1 FY2020Mar 31, 2020$164.00M-28.1%
Q4 FY2019Dec 31, 2019$176.00M+22.2%
Q3 FY2019Sep 30, 2019$203.00M-36.8%
Q2 FY2019Jun 30, 2019$236.00M-3.7%
Q1 FY2019Mar 31, 2019$228.00M+113.1%
Q4 FY2018Dec 31, 2018$144.00M-40.2%
Q3 FY2018Sep 30, 2018$321.00M+7.4%
Q2 FY2018Jun 30, 2018$245.00M+7.0%
Q1 FY2018Mar 31, 2018$107.00M-30.5%
Q4 FY2017Dec 31, 2017$241.00M+8.1%
Q3 FY2017Sep 30, 2017$299.00M–
Q2 FY2017Jun 30, 2017$229.00M–
Q1 FY2017Mar 31, 2017$154.00M–
Q4 FY2016Dec 31, 2016$223.00M–

More Quest Diagnostics figures

See a number that looks wrong?